Welcome to the e-CCO Library Archive!
Analysis of outcomes after non-medical switching of anti-tumor necrosis factor agents
D.T. Rubin*1, M. Skup2, S. Johnson3, J. Chao2, A. Gibofsky4
1University of Chicago , Medicine, Chicago, United States, 2AbbVie Inc., Global Health Economics & Outcomes Research, North Chicago, United States, 3Medicus Economics, LLC, , Milton, United States, 4Hospital for Special Surgery & Weill Cornell Medical College, , New York, United States
Safety and efficacy of restorative proctocolectomy in the elderly. A European, prospective, multicenter, S-ECCO study
F. Colombo1, A. de Buck2, S. Sahami3, A. D'Hoore2, W. Bemelman3, Y. Panis4, G. Sampietro5, 1Luigi Sacco University Hosptal, Department of Surgery, Milano, Italy, 2University Hospitals Gasthuisberg, Department of Abdominal Surgery, Leuven, Belgium, 3Academic Medical Center, Surgery, Amsterdam, Netherlands, 4Hôpital Beaujon, Pole des Maladies de L'Appareil Digestif, Clichy, France, 5Luigi Sacco University Hospital. IBD Surgical Unit, Department of Surgery, Milano, Italy
M. Nakano1, K. Tominaga1, M. Hoshino1, K. Kanke1, H. Hiraishi1, 1Dokkyo Medical University, Department of Gastroenterology, Mibu-machi, Japan
What is treat-to-target of Crohn's Disease: the comparison of long-term outcome among patients with mucosal healing, deep remission and biological remission ?
Y. Qiu*, R. Mao, B.-l. Chen, Y. He, Z.-r. Zeng, M.-h. Chen
First Affiliated Hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China
Safety and PK results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor agonist
A. Olson1, J. Hartung2, G. Timony3, R. Peach4, M. Boehm5, H. Smith2, S. Gujrathi6, 1Receptos, Clinical Development, San Diego, United States, 2Receptos, Clinical Operations, San Diego, United States, 3Receptos, Preclinical Sciences, San Diego, United States, 4Receptos, CSO, San Diego, United States, 5Receptos, CTO, San Diego, United States, 6Receptos, CMO, San Diego, United States
N. Khan1, A. Abbas2, A. Williamson2, L. Balart2, 1Southeast Louisiana Veterans Health Care System, Gastroenterology, New Orleans, United States, 2Tulane University, Gastroenterology, New Orleans, United States
Durable Clinical Remission and Response in Adalimumab-Treated Patients with Ulcerative Colitis
R. Panaccione*1, J.-F. Colombel2, W.J. Sandborn3, W. Reinisch4, 5, G. D'Haens6, D. Hommes7, S. Ghosh1, B. Pappalardo8, J. Petersson8, A.M. Robinson8, A. Lazar9, Q. Zhou8, R.B. Thakkar8
1University of Calgary, Department of Medicine, Calgary, Canada, 2Icahn School of Medicine at Mount Sinai, Gastroenterology, New York City, United States, 3University of California San Diego, Gastroenterology, La Jolla, CA, United States, 4McMaster University, Gastroenterology, Hamilton, Canada, 5Medical University of Vienna, Dept. for Gastroenterology and Hepatology, Vienna, Austria, 6Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, 7University of California, Gastroenterology, Los Angeles, CA, United States, 8AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, United States, 9AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany
Role of THD in patients affected by Crohn's disease and haemorrhoidal disease: a preliminary study
G. Giarratano1, A. Stazi1, C. Toscana2, L. Franceschilli3, A. Gaspari3, P. Sileri3, 1Clinica Madonna delle Grazie, Surgery, Velletri, Italy, 2Clinica Villa Tiberia, Surgery, Rome, Italy, 3University of Rome Tor Vergata, Department of Sperimental medicine and Surgery, Rome, Italy
C. Zeglinas1, I. Papaconstantinou2, M. Gazouli3, C. Nastos2, A. Yiallourou2, C. Evagelou4, I. Vlahogiannakos5, K. Tsimaratou3, A. Papalois6, C. Tzathas1, 1Tzaneion, Gastroenterology, Piraeus, Greece, 2Areteion, Surgery, Athens, Greece, 3Molecular carcinigenesis group, Laboratory of Histology and Embryology, Athens, Greece, 4Medical School, Pathology, Athens, Greece, 5Laikon Hospital, Internal Medicine, Athens, Greece, 6Experimental-Research Unit, ELPEN-Pharmaceuticals Co. Inc, Pikermi, Greece
Integrated care pathways for Inflammatory Bowel Disease Surgery: Design and first analysis.
R. Jacobs*1, 2, S. Reardon3, D. Sagar1, T.J. Hommes1, 2, D. Margolis4, E. Kane1, W.K. Van Deen1, L. Eimers1, E.K. Inserra1, N. Duran1, J.M. Choi1, C.Y. Ha1, B. Roth1, A.D. Ho1, E. Esrailian1, J. Sack3, D.W. Hommes1
1UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, Los Angeles, United States, 2LUMC, Gastroenterology and Hepatology, Leiden, Netherlands, 3UCLA, Division of General Surgery, Los Angeles, United States, 4UCLA, Division of Radiological Sciences, Los Angeles, United States
Risk of incident cancer in patients with inflammatory bowel disease starting anti-TNF therapy while having prior malignancy within past 5 years (GETAID survey)
F. Poullenot1, P. Seksik2, L. Beaugerie2, A. Amiot3, M. Nachury4, V. Abitbol5, C. Stefanescu6, C. Reenaers7, M. Fumery8, A.-L. Pelletier9, S. Nancey10, L. Peyrin-Biroulet11, A. Bourreille12, X. Hebuterne13, H. Brixi14, G. Savoye15, N. Lourenco16, R. Altwegg17, G. Bommelaer18, C. Cazelles-Boudier19, A. Racine20, D. Laharie1, 1CHU de Bordeaux, Gastroenterologie, Pessac, France, 2Hopital Saint-Antoine – APHP, Gastroenterologie, Paris, France, 3Hôspital Henri-Mondor, Gastroenterologie, Creteil, France, 4CHU de Lille, Gastroenterologie, Lille, France, 5Hopital Cochin – APHP, Gastroenterologie, Paris, France, 6Hopital Beaujon – APHP, Gastroenterologie, Clichy, France, 7CHU de Liege, Gastroenterologie, Liege, Belgium, 8CHU de Amiens, Gastroenterologie, Amiens, France, 9Hopital Bichat – APHP, Gastroenterologie, Paris, France, 10Hopital Lyon Sud – APHL, Gastroenterologie, Pierre-Benite, France, 11CHU de Nancy, Gastroenterologie, Vandoeuvre-les-Nancy, France, 12CHU de Nantes, Gastroenterologie, Nantes, France, 13CHU de Nice, Gastroenterologie, Nice, France, 14CHU de Reims, Gastroenterologie, Reims, France, 15CHU de Rouen, Gastroenterologie, Rouen, France, 16Hopital Saint-Louis – APHP, Gastroenterologie, Paris, France, 17CHU de Montpellier, Gastroenterologie, Montpellier, France, 18CHU de Clermont-Ferrand, Gastroenterologie, Clermont-Ferrand, France, 19CH de Bayonne, Gastroenterologie, Bayonne, France, 20Hôpital du Kremlin-Bicetre – APHP, Gastroenterologie, Kremlin-Bicetre, France